MEXCLAV ™

MEXCLAV 250 MG TABLET
Generic : Cefuroxime 250 + Clavulanic acid 62.5
Thearapeutic : Antibiotics
Pack Size : 14 s(Pc(s))
Strength :
Dosage Form : Tablet

Mexclav

Cefuroxime

COMPOSITION

  • Mexclav 250 Tablet: Each film-coated tablet contains Cefuroxime Axetil USP equivalent to Cefuroxime 250 mg & Clavulanate potassium USP equivalent to Clavulanic Acid 62.5 mg.
  • Mexclav 500 Tablet: Each film-coated tablet contains Cefuroxime Axetil USP equivalent to Cefuroxime 500 mg & Clavulanate potassium USP equivalent to Clavulanic Acid 125 mg.

DESCRIPTION

  • Cefuroxime is one of the bactericidal second-generation cephalosporin antibiotics, which is active against a wide range of Gram-positive and Gram-negative susceptible organisms including many beta-lactamase-producing strains. It is indicated for the treatment of infections caused by sensitive bacteria.
  • Clavulanic Acid has a similar structure to the beta-lactam antibiotics but binds irreversibly to the beta-lactamase enzymes.
  • The presence of Clavulanic Acid in Mexclav formulations protects Cefuroxime from degradation by beta-lactamase enzymes and effectively extends the antibacterial spectrum of Cefuroxime to include many bacteria normally resistant to Cefuroxime and other cephalosporins.

INDICATIONS & USES

  • Pharyngitis/tonsillitis caused by Streptococcus pyogenes
  • Acute bacterial otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase-producing strains), Moraxella catarrhalis (including beta-lactamase-producing strains) or Streptococcus pyogenes
  • Acute bacterial maxillary sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (nonbetazzaa lactamase-producing strains only)
  • Lower respiratory tract infections including pneumoniae, caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase-producing strains), Klebsiella spp., Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus pyogenes, Escherichia coli.
  • Acute bacterial exacerbations of chronic bronchitis and secondary bacterial infections of acute bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae (beta-lactamase negative strains) or Haemophilus parainfluenzae (beta-lactamase negative strains)
  • Skin and Skin-Structure infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus pyogenes, Escherichia coli, Klebsiella spp., and Enterobacter spp.
  • Urinary tract infections caused by Escherichia coli or Klebsiella pneumonia
  • Bone and Joint infections caused by Staphylococcus aureus (penicillinase and non-penicillinase-producing strains)
  • Gonorrhea: Uncomplicated and disseminated gonococcal infections due to Neisseria gonorrhoeae (penicillinase and non-penicillinase-producing strains) in both males and females
  • Early Lyme disease (erythema migrans) caused by Borrelia burgdorferi
  • Septicemia caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae (including ampicillin-resistant strains), and Klebsiella spp.
  • Meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Neisseria meningitis, and Staphylococcus aureus (penicillinase and non-penicillinase producing strains) Switch therapy (injectable to oral) after surgery when patient's condition is improved.
  • DOSAGE AND ADMINISTRATION
  • Adolescents and Adults

Biopharma Ltd. Produces MEXCLAV 250 MG TABLET it is a trusted product for alleviating various discomforts, and it's commonly found in pharmacies and stores.

BIOPHARMA   AFFILIATE  COMPANIES